<DOC>
	<DOCNO>NCT00031759</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain substance try prevent development cancer . Applying topical imiquimod abnormal cervical cell remove may effective prevent cervical cancer . PURPOSE : Randomized phase II trial study effectiveness apply topical imiquimod abnormal cervical cell remove prevent cervical cancer patient recurrent persistent cervical neoplasia .</brief_summary>
	<brief_title>Imiquimod Preventing Cervical Cancer Women With Cervical Neoplasia</brief_title>
	<detailed_description>OBJECTIVES : - Compare chemopreventive efficacy topical imiquimod follow local ablative excisional therapy v ablative/excisional therapy alone patient recurrent high-grade cervical intraepithelial neoplasia . - Compare toxicity regimens patient . - Compare quality life patient treat regimen . - Determine safety tolerability imiquimod patient . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , disease ( primary v recurrent persistent ) , severity dysplasia ( grade I vs grade II v grade III ) , current tobacco use ( yes v ) , plan surgical procedure ( excisional v laser v cryotherapy v ) , time since first abnormal Pap smear , include pathology ascus favor dysplasia ( less 1 year v 1-3 year vs 3 year ) . Patients randomize one two treatment arm . - Arm I : Patients undergo ablative excisional therapy . - Arm II : Patients topical imiquimod apply cervix 6-10 hour twice weekly total 5 dos . Within 3-4 week final application , patient undergo ablative excisional therapy . Quality life assess baseline , last dose study drug ( arm II ) , 3-5 day ablation excisional therapy , 3 month , annually thereafter . Patients follow every 3-4 month 2 consecutive normal Pap smear colposcopic exam , every 6 month 2 year , annually 5 year completion study therapy . PROJECTED ACCRUAL : A total 66-152 ( 33-76 per treatment arm ) accrue study within 18 month .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary grade II III cervical intraepithelial neoplasia ( CIN ) persistent grade IIII CIN ( dysplasia new require treatment ) Squamous cell lesion involve endocervix colposcopy OR colposcopy negative cytobrush endocervical curettage No untreated cervical vaginal infection human papilloma virus No desire hysterectomy ablative therapy PATIENT CHARACTERISTICS : Age : 18 Life expectancy : At least 5 year Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study HIV negative No AIDS No know hypersensitivity imiquimod No latex allergy PRIOR CONCURRENT THERAPY : Other : No concurrent immunosuppressive therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>cervical cancer</keyword>
	<keyword>cervical intraepithelial neoplasia grade 1</keyword>
	<keyword>cervical intraepithelial neoplasia grade 2</keyword>
	<keyword>cervical intraepithelial neoplasia grade 3</keyword>
</DOC>